Login / Signup

Nine-year prospective efficacy and safety of brain-responsive neurostimulation for focal epilepsy.

Dileep R NairKenneth D LaxerPeter B WeberAnthony M MurroYong D ParkGregory L BarkleyBrien J SmithRyder P GwinnMichael J DohertyKatherine H NoeRichard S ZimmermanGregory K BergeyWilliam S AndersonChristianne HeckCharles Y LiuRicky W LeeToni SadlerRobert B DuckrowLawrence J HirschRobert E WharenWilliam TatumShraddha SrinivasanGuy M McKhannMark A AgostiniAndreas V AlexopoulosBarbara C JobstDavid W RobertsVicenta SalanovaThomas C WittSydney S CashAndrew J ColeGregory A WorrellBrian N LundstromJonathan C EdwardsJonathan J HalfordDavid C SpencerLia ErnstChristopher T SkidmoreMichael R SperlingIan MillerEric B GellerMichel J BergA James FesslerPaul RuteckiAlica M GoldmanEli M MizrahiRobert E GrossDonald C ShieldsTheodore H SchwartzDouglas R LabarNathan B FountainW Jeff EliasPiotr W OlejniczakNicole R Villemarette-PittmanStephan EisenschenkSteven N RoperJane G BoggsTracy A CourtneyFelice T SunCairn G SealeKathy L MillerTara L SkarpaasMartha J Morrellnull null
Published in: Neurology (2020)
This study provides Class IV evidence that brain-responsive neurostimulation significantly reduces focal seizures with acceptable safety over 9 years.
Keyphrases
  • resting state
  • white matter
  • cancer therapy
  • functional connectivity
  • multiple sclerosis
  • drug delivery
  • temporal lobe epilepsy
  • brain injury
  • blood brain barrier
  • subarachnoid hemorrhage